Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2



Status:Completed
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/9/2018
Start Date:April 28, 2015
End Date:February 22, 2017

Use our guide to learn which trials are right for you!

A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial With Nab-Paclitaxel (ABRAXANE®) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2)

4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by
nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4
cycles.


Inclusion Criteria:

- General and Demographics

1. Age ≥ 18 years of age at the time of signing the Informed Consent Form.

2. Understand and voluntarily provide written consent to the Informed Consent Form
prior to conducting any study related assessments/procedures.

3. Able to adhere to the study visit schedule and other protocol requirements.
Disease Specific

4. Histologically or cytologically confirmed Stage IIIB or IV Non-Small Cell Lung
Cancer.

5. Radiographically documented measurable disease at study entry per response
evaluation criteria in solid tumours ( RECIST) v1.1.

6. No prior anti-cancer therapy for the treatment of metastatic disease at the time
of signing the ICF. Adjuvant treatment is permitted providing cytotoxic
chemotherapy was completed 12 months prior to signing the ICF and without disease
recurrence.

7. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3.

8. Platelets ≥ 100,000 cells/mm3.

9. Hemoglobin (Hgb) ≥ 9 g/dL.

10. Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase [SGOT]),
alanine transaminase (ALT/serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 ×
upper limit of normal range (ULN) or ≤ 5.0 × ULN if liver metastases.

11. Total bilirubin ≤ 1.5 × ULN except in cases of Gilbert's disease and liver
metastases.

12. Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance ≥ 40 mL/min (if
renal impairment is suspected 24-hour urine collection for measurement is
required).

13. Eastern Cooperative Oncology Group Performance Status 2.

14. Females of childbearing potential [defined as a sexually mature woman who (1)
have not undergone hysterectomy (the surgical removal of the uterus) or bilateral
oophorectomy (the surgical removal of both ovaries) or (2) have not been
naturally postmenopausal for at least 24 consecutive months (ie, has had menses
at any time during the preceding 24 consecutive months)] must:

1. Have a negative pregnancy test Beta Human Chorionic Gonaditrophin(ß-hCG) as
verified by the study doctor within 72 hours prior to starting study
therapy.

2. You must commit to complete abstinence from heterosexual contact, or agree
to use medical doctor-approved contraception throughout the study without
interruption; while receiving study medication or for a longer period if
required by local regulations.

Male subjects must:

3. practice true abstinence* or agree to use a condom during sexual contact
with a pregnant female or a female of childbearing potential while
participating in the study, during dose interruptions and for at least 6
months following study drug discontinuation, even if he has undergone a
successful vasectomy.

Exclusion Criteria:

- The presence of any of the following will exclude a subject from enrollment:

1. Evidence of active brain metastases, including leptomeningeal involvement (prior
evidence of brain metastasis are permitted only if treated and stable and off
therapy for at least 21days prior to signing ICF). MRI of the brain (or CT scan
w/contrast) is preferred for diagnosis.

2. History of leptomeningeal disease.

3. Only evidence of disease is non-measurable.

4. Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Criteria for Adverse
Events (CTCAE) v4.0).

5. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for
palliation ≤ 2 weeks prior to starting investigational product (IP), and/or from
whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target
lesion is permitted only if there has been clear progression of the lesion since
radiation was completed.

6. Venous thromboembolism within 1 month prior to signing ICF.

7. Current congestive heart failure (New York Heart Association Class II-IV).

8. History of the following within 6 months prior to first administration of
investigational product: a myocardial infarction, severe/unstable angina
pectoris, coronary/peripheral artery bypass graft, New York Heart Association
(NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically
significant cardiac dysrhythmia or clinically significant ECG abnormality,
cerebrovascular accident, transient ischemic attack, or seizure disorder.

9. Subject has a known infection with hepatitis B or C, or history of human
immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or
myelosuppressive medications that would in the opinion of the investigator,
increase the risk of serious neutropenic complications.

10. Subject has an active, uncontrolled bacterial, viral, or fungal infection(s)
requiring systemic therapy, defined as ongoing signs/symptoms related to the
infection without improvement despite appropriate antibiotics, antiviral therapy,
and/or other treatment.

11. History of interstitial lung disease, sarcoidosis, silicosis, idiopathic
pulmonary fibrosis, or pulmonary hypersensitivity pneumonitis.

12. Treatment with any investigational product within 28 days prior to signing the
ICF.

13. History of or suspected allergy to nab-paclitaxel, carboplatin and human albumin
or any other platinum-based therapy.

14. Currently enrolled in any other clinical protocol or investigational trial that
involves administration of experimental therapy and/or therapeutic devices.

15. Any other clinically significant medical condition, psychiatric illness, and/or
organ dysfunction that will interfere with the administration of the therapy
according to this protocol or which, in the views of investigator, preclude
combination chemotherapy.

16. Subject has any other malignancy within 5 years prior to signing the ICF.
Exceptions include the following: squamous cell carcinoma of the skin, in-situ
carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ
of the breast, or incidental histological finding of prostate cancer (Tumor, node
and metastasis (TNM) stage of T1a or T1b). All treatment should have been
completed 6 months prior to signing ICF.

17. Any condition including the presence of laboratory abnormalities, which places
the subject at unacceptable risk if he/she were to participate in the study.

18. Any medical condition that confounds the ability to interpret data from the
study. This includes subjects with known psychiatric disorders.

19. Pregnant or breast-feeding females.

20. Subjects with an ECOG PS other than 2
We found this trial at
8
sites
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
234 Goodman Dr
Cincinnati, Ohio 45229
(513) 584-1000
University of Cincinnati Medical Center Opening in 1823 as the country
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Boynton Beach, Florida 33426
?
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
Rochester, NY
Click here to add this to my saved trials
750 East Adams Street
Syracuse, New York 13210
?
mi
from
Syracuse, NY
Click here to add this to my saved trials